Showing results (561-570 of 3,788) with videos related to
Sort By:
Pageof 379
Oncoimmunology|January 4, 2018
BTN3A is a prognosis marker and a promising target for Vγ9Vδ2 T cells based-immunotherapy in pancreatic ductal adenocarcinoma (PDAC)Audrey Benyamine, Céline Loncle, Etienne Foucher, et al.Oncoimmunology|January 4, 2018
Langerhans-type dendritic cells electroporated with TRP-2 mRNA stimulate cellular immunity against melanoma: Results of a phase I vaccine trialDavid J Chung, Richard D Carvajal, Michael A Postow, et al.Oncoimmunology|January 4, 2018
IL-17 induces antitumor immunity by promoting beneficial neutrophil recruitment and activation in esophageal squamous cell carcinomaChang-Long Chen, Ying Wang, Chun-Yu Huang, et al.Oncoimmunology|January 4, 2018
Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancerHye In Kim, Mijin Kim, Se-Hoon Lee, et al.Oncoimmunology|January 4, 2018
Blocking CTLA-4 while priming with a whole cell vaccine reshapes the oligoclonal T cell infiltrate and eradicates tumors in an orthotopic glioma modelCameron S Field, Martin K Hunn, Peter M Ferguson, et al.Oncoimmunology|January 4, 2018
Crk adaptor protein promotes PD-L1 expression, EMT and immune evasion in a murine model of triple-negative breast cancerSushil Kumar, Viralkumar Davra, Alison E Obr, et al.Oncoimmunology|January 4, 2018
Interleukin-21 combined with PD-1 or CTLA-4 blockade enhances antitumor immunity in mouse tumor modelsKatherine E Lewis, Mark J Selby, Gregg Masters, et al.Oncoimmunology|January 4, 2018
Bevacizumab-mediated tumor vasculature remodelling improves tumor infiltration and antitumor efficacy of GD2-CAR T cells in a human neuroblastoma preclinical modelPaola Bocca, Emma Di Carlo, Ignazio Caruana, et al.Oncoimmunology|January 4, 2018
IL-21 promotes the development of a CD73-positive Vγ9Vδ2 T cell regulatory populationClément Barjon, Henri-Alexandre Michaud, Angeline Fages, et al.Pageof 379